top of page

- 0 min read

Vivacelle Bio - Biotech Executive Conversations

Recent Posts

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio , a late-stage biopharma company developing life-saving treatments for...

Surge in Septic Shock Care: Vivacelle’s Innovative Approach

Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock

ความคิดเห็น

bottom of page